CD44 and familial pancreatic carcinoma: Of xenograft cells receiving gemcitabine treatment, 32% were CD24+ CD44+ ESA+ cells, compared with 0.8% of control pancreatic cancer cells receiving vehicle treatment (Fig. 1F).